ArticleBiomaterials2022
Chemically-defined generation of human hemogenic endothelium and definitive hematopoietic progenitor cells.
Article in Biomaterials, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 16 citations in OpenAlex.
- Hematopoietic organoids: Opportunities and challenges in modeling human hematopoiesis and diseases in vitro.Stem cell reports · 2026Review
- The p53-miR17 family-Rankl axis bridges liver-bone communication.Molecular therapy : the journal of the American Society of Gene Therapy · 2025Article
- Forward programming of hPSCs to neutrophils using chemically defined media.Stem cell research & therapy · 2025Article
- Advancements in adoptive CAR immune cell immunotherapy synergistically combined with multimodal approaches for tumor treatment.Bioactive materials · 2024Review
- Rapid conversion of porcine pluripotent stem cells into macrophages with chemically defined conditions.The Journal of biological chemistry · 2024Article
- Generation of chimeric antigen receptor macrophages from human pluripotent stem cells to target glioblastoma.Immuno-oncology technology · 2023Article
- Engineered hematopoietic and immune cells derived from human pluripotent stem cells.Experimental hematology · 2023Review
- Engineered human pluripotent stem cell-derived natural killer cells with PD-L1 responsive immunological memory for enhanced immunotherapeutic efficacy.Bioactive materials · 2023Article
- Engineered anti-prostate cancer CAR-neutrophils from human pluripotent stem cells.Journal of immunology and regenerative medicine · 2023Article
- CAR-neutrophil mediated delivery of tumor-microenvironment responsive nanodrugs for glioblastoma chemo-immunotherapy.Nature communications · 2023Article
- Adoptive Immunotherapy: A Human Pluripotent Stem Cell Perspective.Cells, tissues, organs · 2023Review
- Engineering chimeric antigen receptor neutrophils from human pluripotent stem cells for targeted cancer immunotherapy.Cell reports · 2022Article
- Temporal Expression of Transcription FactorACS synthetic biology · 2022Article
- Wnt signaling directs human pluripotent stem cells into vascularized cardiac organoids with chamber-like structures.Frontiers in bioengineering and biotechnology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 4 institutions in 1 country.
Funding
Abstract
Human hematopoietic stem cells (HSCs), which arise from aorta-gonad-mesonephros (AGM), are widely used to treat blood diseases and cancers. However, a technique for their robust generation in vitro is still missing. Here we show temporal manipulation of Wnt signaling is sufficient and essential to induce AGM-like hematopoiesis from human pluripotent stem cells. TGFβ inhibition at the stage of aorta-like SOX17
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.